A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase I trial tests the safety, side effects, and best dose of imetelstat in combination with fludarabine and cytarabine in treating patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) or juvenile myelomonocytic leukemia (JMML) that has not responded to previous treatment (refractory) or that has come back after a period of improvement (recurrent). Imetelstat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as fludarabine and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving imetelstat in combination with fludarabine and cytarabine may work better in treating patients with refractory or recurrent AML, MDS, and JMML.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek od 1 roku do 18 lat w momencie włączenia do badania
- •Rozpoznanie białaczki mieloidalnej (w tym związanej z poprzednim leczeniem), zespołu mielodysplastycznego lub choroby mielomononuklearnej, w tym z zespołem Downa
- •Druga lub kolejna nawrót białaczki mieloidalnej, lub choroba oporyczna na leczenie
- •Pierwsza lub kolejna nawrót zespołu mielodysplastycznego
- •Pierwsza lub kolejna nawrót choroby mielomononuklearnej
- •Badania szpiku kości wykazujące obecność atypowych komórek białaczkowych w określonym procencie
Simplified criteria — AI translation
Trial details
- Minimum age
- 1 Year
- Maximum age
- 18 Years
- Last updated (source)
- August 25, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (19)
Children's Hospital of Alabama
Birmingham, United States
Children's Hospital of Orange County
Orange, United States
UCSF Medical Center-Mission Bay
San Francisco, United States
Children's Hospital Colorado
Aurora, United States
Children's National Medical Center
Washington D.C., United States
Children's Healthcare of Atlanta - Arthur M Blank Hospital
Atlanta, United States
Lurie Children's Hospital-Chicago
Chicago, United States
Riley Hospital for Children
Indianapolis, United States
Dana-Farber Cancer Institute
Boston, United States
C S Mott Children's Hospital
Ann Arbor, United States
University of Minnesota/Masonic Cancer Center
Minneapolis, United States
Washington University School of Medicine
St Louis, United States
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
New York, United States
Cincinnati Children's Hospital Medical Center
Cincinnati, United States
Children's Hospital of Philadelphia
Philadelphia, United States
Children's Hospital of Pittsburgh of UPMC
Pittsburgh, United States
Saint Jude Children's Research Hospital
Memphis, United States
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
Houston, United States
Seattle Children's Hospital
Seattle, United States
Trial contact
Site Public Contact
Girish Dhall
PRINCIPAL_INVESTIGATOR
Site Public Contact
Elyssa M. Rubin
PRINCIPAL_INVESTIGATOR
Site Public Contact
Kieuhoa T. Vo
PRINCIPAL_INVESTIGATOR
Site Public Contact
Margaret E. Macy
PRINCIPAL_INVESTIGATOR
Site Public Contact
AeRang Kim
PRINCIPAL_INVESTIGATOR
Site Public Contact
Jason R. Fangusaro
PRINCIPAL_INVESTIGATOR
Site Public Contact
Sara Zarnegar-Lumley
PRINCIPAL_INVESTIGATOR
Site Public Contact
Brian D. Weiss
PRINCIPAL_INVESTIGATOR
Site Public Contact
Jonathan Paolino
PRINCIPAL_INVESTIGATOR
Site Public Contact
Rajen Mody
PRINCIPAL_INVESTIGATOR
Site Public Contact
Robin L. Williams
PRINCIPAL_INVESTIGATOR
Site Public Contact
Shalini Shenoy
PRINCIPAL_INVESTIGATOR
Site Public Contact
Nobuko Hijiya
PRINCIPAL_INVESTIGATOR
Site Public Contact
Joseph G. Pressey
PRINCIPAL_INVESTIGATOR
Site Public Contact
Sarah K. Tasian
PRINCIPAL_INVESTIGATOR
Site Public Contact
Andrew Bukowinski
PRINCIPAL_INVESTIGATOR
Site Public Contact
Matthew Rees
PRINCIPAL_INVESTIGATOR
Site Public Contact
Alexandra M. Stevens
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/26/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.